Cargando…

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation

The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsing-remitting form of multiple sclerosis (RRMS). Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham polyomavirus (JCV) and development of progressive multifocal leuk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iannetta, Marco, Zingaropoli, Maria Antonella, Bellizzi, Anna, Morreale, Manuela, Pontecorvo, Simona, D’Abramo, Alessandra, Oliva, Alessandra, Anzivino, Elena, Lo Menzo, Sara, D’Agostino, Claudia, Mastroianni, Claudio Maria, Millefiorini, Enrico, Pietropaolo, Valeria, Francia, Ada, Vullo, Vincenzo, Ciardi, Maria Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972347/ https://www.ncbi.nlm.nih.gov/pubmed/27486658 http://dx.doi.org/10.1371/journal.pone.0160277

Ejemplares similares

Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients
por: Iannetta, Marco, et al.
Publicado: (2019)

JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus
por: Zingaropoli, Maria A., et al.
Publicado: (2018)

Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment
por: Pietropaolo, Valeria, et al.
Publicado: (2015)

HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity
por: Iannetta, Marco, et al.
Publicado: (2013)

Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients
por: D’Abramo, Alessandra, et al.
Publicado: (2016)

Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin
por: D'Abramo, Alessandra, et al.
Publicado: (2013)

Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis
por: D'Abramo, Alessandra, et al.
Publicado: (2014)

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
por: Schwab, Nicholas, et al.
Publicado: (2016)

Severe Bloodstream Infection due to KPC-Producer E coli in a Renal Transplant Recipient Treated With the Double-Carbapenem Regimen and Analysis of In Vitro Synergy Testing: A Case Report
por: Oliva, Alessandra, et al.
Publicado: (2016)

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients
por: Dwyer, Christopher M., et al.
Publicado: (2021)

Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis
por: Ciardi, Maria R, et al.
Publicado: (2018)

JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis
por: Ciardi, Maria Rosa, et al.
Publicado: (2020)

Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug
por: Javed, Adil, et al.
Publicado: (2016)

Severe Plasmodium ovale malaria complicated by acute respiratory distress syndrome in a young Caucasian man
por: D’Abramo, Alessandra, et al.
Publicado: (2018)

Bag3-Induced Autophagy Is Associated with Degradation of JCV Oncoprotein, T-Ag
por: Sariyer, Ilker Kudret, et al.
Publicado: (2012)

Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study
por: Russo, Gianluca, et al.
Publicado: (2021)

Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study
por: Bellizzi, Anna, et al.
Publicado: (2013)

Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay
por: Campagnolo, Denise, et al.
Publicado: (2016)

Viral tumor antigen expression is no longer required in radiation-resistant subpopulation of JCV induced mouse medulloblastoma cells
por: Donadoni, Martina, et al.
Publicado: (2018)

Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment
por: Prezioso, Carla, et al.
Publicado: (2022)

The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit
por: Ceccarelli, Giancarlo, et al.
Publicado: (2015)

Major reduction of NKT cells in patients with severe COVID-19 pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2021)

Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study
por: Conte, Antonella, et al.
Publicado: (2015)

Persistent detection of dengue virus RNA in vaginal secretion of a woman returning from Sri Lanka to Italy, April 2017
por: Iannetta, Marco, et al.
Publicado: (2017)

JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?
por: Diotti, Roberta Antonia, et al.
Publicado: (2013)

JCV seroconversion rate during the SARS COVID-19 pandemic
por: Vigiser, I., et al.
Publicado: (2022)

Correction: The unmet need for COVID-19 treatment in immunocompromised patients
por: D’Abramo, Alessandra, et al.
Publicado: (2023)

The unmet need for COVID-19 treatment in immunocompromised patients
por: Alessandra, D’Abramo, et al.
Publicado: (2022)

Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)

The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
por: Ciardi, Maria Rosa, et al.
Publicado: (2020)

H-magnetic resonance spectroscopy: diagnostic tool in recurrent headache in systemic lupus erythematosus. A case report
por: Tinelli, Emanuele, et al.
Publicado: (2018)

Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection
por: Vita, Serena, et al.
Publicado: (2020)

No detection of EBV, BKV and JCV in breast cancer tissue samples in Iran
por: Dowran, Razieh, et al.
Publicado: (2019)

Anti-JCV antibody index does not change during ocrelizumab-treatment
por: Rempe, Torge, et al.
Publicado: (2020)

Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2021)

Persistent Systemic Microbial Translocation, Inflammation, and Intestinal Damage During Clostridioides difficile Infection
por: Oliva, Alessandra, et al.
Publicado: (2019)

New Insights on Human Polyomavirus JC and Pathogenesis of Progressive Multifocal Leukoencephalopathy
por: Bellizzi, Anna, et al.
Publicado: (2013)

Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients
por: Marocco, Raffaella, et al.
Publicado: (2022)

Primary bilateral adrenal B-cell lymphoma associated with EBV and JCV infection
por: Barzon, Luisa, et al.
Publicado: (2009)

JC Virus Encephalopathy Is Associated with a Novel Agnoprotein-Deletion JCV Variant
por: Dang, Xin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bdc49fenp8ke4seg6984n3last